Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper - GI, colorectal

398O - Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer (CRC) - PRODIGE 13 a FFCD phase III trial


19 Sep 2020


Proffered Paper - GI, colorectal


Tumour Site

Colon and Rectal Cancer


Come Lepage


Annals of Oncology (2020) 31 (suppl_4): S409-S461. 10.1016/annonc/annonc270


C. Lepage1, J.M. Phelip2, L. CANY3, E. Barbier4, S. Manfredi5, P. Deguiral6, R. Faroux7, M. Baconnier8, D. Pezet9, J. Duchmann10, E. Terrebonne11, A. Adenis12, M. Benabdelghani13, J. Ain14, G. Breysacher15, I. Boillot-Benedetto16, A. Pelaquier17, P. Prost18, A. Lievre19, O. Bouche20

Author affiliations

  • 1 Hepato Gastroenterology And Digestive Oncology, CHU Dijon, 21079 - Dijon/FR
  • 2 Gastroenterology And Gi Oncology, CHU Saint Etienne - Hopital Nord, 42055 - Saint-Étienne/FR
  • 3 Radiotherapy & Oncology, Polyclinique Francheville, Perigueux/FR
  • 4 Biostatistics, Fédération Francophone de Cancérologie Digestive, 21079 - Dijon/FR
  • 5 Hepato-gastroenterology, Le Bocage Hospital and INSERM U1231, 21079 - Dijon/FR
  • 6 Oncology, Clinique Mutualiste de l'Estuaire, Saint Nazaire/FR
  • 7 Hepato-gastroenterology And Digestive Oncologyépatogastroenterology And Digestive Oncology, Centre Hospitalier Les Oudairies, 85000 - La Roche sur Yon/FR
  • 8 Medical Oncology, Centre Hospitalier Annecy-Genevois, 74000 - Annecy/FR
  • 9 Surgical Oncology, CHU Estaing, Clermont Ferrand/FR
  • 10 Gastroenterology And Gi Oncology, CH Compiègne, Compiègne/FR
  • 11 Hepato-gastoenterology Department, Haut Lévêque Hospital, 33604 - Pessac/FR
  • 12 Medical Oncology Department, Anti cancer center Oscar Lambret, Lille/FR
  • 13 Medical Oncology, Centre Paul Strauss, Strasbourg/FR
  • 14 Surgical Oncology, polyclinique Val de Saône, Mâcon/FR
  • 15 68, Hopital Louis Pasteur, 68024 - Colmar/FR
  • 16 Surgery, CH St Joseph-St Luc, Lyon/FR
  • 17 Gastroenterology And Gi Oncology, Centre Hospitalier Montelimar Service de Oncologie, 26200 - Montelimar/FR
  • 18 Gastroenterology And Gi Oncology, CH Fleyriat, Bourg en Bresse/FR
  • 19 Gastroenterology And Gi Oncology, CHU Rennes - Hôpital Pontchaillou, 35033 - Rennes/FR
  • 20 Gastroenterology And Gi Oncology, CHU de Reims - Hôpital Robert Debré, 51092 - Reims/FR


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 398O


Intensive follow-up of patients (pts) after curative surgery for CRC is recommended by various scientific societies. These recommendations are mainly based on expert opinions and results of the few clinical trials performed are controversial. Moreover, no survival benefit has been demonstrated.


PRODIGE 131 is a prospective multicentre controlled trial evaluating by double randomisation the impact of i) intensive radiological monitoring (CT-scan/6m) versus a standard one (abdominal ultrasound/3m and thoracic radiography/6m) and ii) CEA assessment versus no, in the follow-up of resected stage II or III CRC with no evidence of residual disease on post-surgical investigation in France and Belgium. The primary endpoint was 5-year overall survival (OS).


Between 09/2009 and 04/2015, 1995 pts were included (75.9%< 75 years old, 16% rectal, 44% left colon cancer (CC)). Among CC 52 % were Stage II (25% received adjuvant chemotherapy). With a median follow-up of 6.5 years, cancer recurrence was detected in 22% of the cases and second CRC in 1.7%. Among recurrences in CC, 8.4% were localized, 74.7% metastatic, and 15.7% both. These pts were treated with curative intent, respectively in 86.7%, 52.3% & 44.6%. Surgical treatment of recurrence with curative intent was 40.9% in the minimum follow-up group (No CEA & standard imaging), 66.3% in the CEA & standard imaging group, 50.7% in the No CEA & CT, and 59.5% in the maximum follow-up group (CEA & CT) (p=0.0035). Among recurrences in rectal cancer, 19.3% were localized, 65% metastatic, and 15.7% both. These pts were treated with curative intent, respectively in 50%, 53.7% & 38.5%. Surgical treatment of recurrence with curative intent was 42.9% in the minimum follow-up group, 57.9% in the CEA group & standard imaging, 55% in the No CEA & CT, and 47.8% in the maximum follow-up group (NS). None of the follow-up modalities resulted in a difference in OS (2nd interim analysis - 455 events).


After curative surgery, the addition of CEA and/or CT does not provide any benefit in 5-year OS, but allows more curative intent secondary surgeries for patients with a more intensive follow-up. Final results of the study will be reported at the meeting. Ref: (1) Lepage Dig Liver Dis. 2015.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study



Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.